申请人:Taisho Pharmaceutical Co., Ltd.
公开号:EP3192798A1
公开(公告)日:2017-07-19
A useful novel compound that shows superior antibacterial activity also against erythromycin resistant bacteria, for example, resistant pneumococci, streptococci, mycoplasmas, and the like, against which sufficient antibacterial activity cannot be obtained with conventional macrolide antibiotics, or a pharmaceutically acceptable salt thereof, or a hydrate or a solvate thereof.
一种有用的新型化合物,它对红霉素耐药菌(例如耐药肺炎球菌、链球菌、支原体等)也具有卓越的抗菌活性,而传统的大环内酯类抗生素无法对这些细菌产生足够的抗菌活性,该化合物或其药学上可接受的盐,或其水合物或溶液。